Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

Fig. 3

Forest plot of odd ratios from patients reporting improvements ≥ MCID by baseline IL-6 tertile for SF-36 PCS score (a), SF-36 MCS score (b), and AM-stiffness (c) for sarilumab 200 mg q2w versus adalimuma12321b 40 mg q2w. *Nominal p < 0.01 for interaction test for patients reporting improvements ≥cvbnm,./MCID (using low IL-6 tertile as the reference group). CI confidence interval, MCID minimal clinically important differences, AM-stiffness duration of morning stiffness, OR odds ratio, PCS physical component summary, SF-36 Short Form 36,VAS visual analog scale

Back to article page